+39 06 72596393

fismed@uniroma2.it

    Narges Nasrollahi

    Visiting Students and Alumni

    Email

    narges.nasrollahi@gmail.com

    Biography

    Narges Nasrollahi is a researcher in Molecular Neuroscience, specializing in FUS-mediated targeted delivery and nanobubbles across the BBB. She holds a patent for synthesizing nanobubbles containing biogeneric drugs for targeted delivery with FUS, registered as a PCT.

    Her innovative research has garnered significant financial support, including a sabbatical grant to Rome from Iran’s MSRT Organization, as well as multiple grants from the Iran Nanotechnology Innovation Council (INIC), the Iran Vice-Presidency for Science and Technology (ISTI), the Iran National Science Foundation (INSF), Iran National Innovation Fund (INIF), and the National Institute of Genetic Engineering and Biotechnology (NIGEB).

    Narges’s outstanding contributions led to her receiving the first-place award at the Phoenix Event organized by the National Elites Foundation. Her project distinguished itself among 500 competing entries, earning her a $20,000 prize. Furthermore, in 2024, she was honored as the Role Model Student at the NIGEB.

    Profiles

    Created with Fabric.js 4.6.0

    Scopus

    Pubmed

    LinkedIn

    Labs

    UltraSound (TheraFus)

    Last 5 articles (scopus)

    opensearch:totalResults = 3
    opensearch:startIndex = 0
    opensearch:itemsPerPage = 3
    @role = request
    @searchTerms = AU-ID(57226827565) OR AU-ID(58976441100)
    @startPage = 0

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/search/scopus?start=0&count=25&query=AU-ID%2857226827565%29+OR+AU-ID%2858976441100%29&apiKey=6ae70c855c11cca26b94ca23c22dcbcf
    @type = application/json

    @_fa = true
    @ref = first
    @href = https://api.elsevier.com/content/search/scopus?start=0&count=25&query=AU-ID%2857226827565%29+OR+AU-ID%2858976441100%29&apiKey=6ae70c855c11cca26b94ca23c22dcbcf
    @type = application/json


    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85189797956

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85189797956?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85189797956&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85189797956&origin=inward

    The impact of hUC MSC–derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity; Science Advances; April 2024; DOI: 10.1126/sciadv.adl3406
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85189797956
    dc:identifier = SCOPUS_ID:85189797956
    eid = 2-s2.0-85189797956
    dc:creator = Aliakbari F.
    prism:publicationName = Science Advances
    prism:issn =
    prism:eIssn = 23752548
    prism:volume = 10
    prism:issueIdentifier = 14
    prism:pageRange =
    prism:coverDate = 2024-04-05
    prism:coverDisplayDate = April 2024
    prism:doi = 10.1126/sciadv.adl3406
    citedby-count = 0

    @_fa = true
    affilname = Robarts Research Institute
    affiliation-city = London
    affiliation-country = Canada

    @_fa = true
    affilname = National Institute for Genetic Engineering and Biotechnology Iran
    affiliation-city = Tehran
    affiliation-country = Iran

    pubmed-id = 38569030
    prism:aggregationType = Journal
    subtype = ar
    subtypeDescription = Article
    article-number = eadl3406
    source-id = 21100457028
    openaccess = 1
    openaccessFlag = true
    value:

    $ = all

    $ = publisherfullgold

    value:

    $ = All Open Access

    $ = Gold

    prism:isbn:

    @_fa =
    $ =

    pii =

    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85143232428

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85143232428?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85143232428&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85143232428&origin=inward

    Viral and non-viral gene therapy using 3D (bio)printing; Journal of Gene Medicine; December 2022; DOI: 10.1002/jgm.3458
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85143232428
    dc:identifier = SCOPUS_ID:85143232428
    eid = 2-s2.0-85143232428
    dc:creator = Jahangiri S.
    prism:publicationName = Journal of Gene Medicine
    prism:issn = 1099498X
    prism:eIssn = 15212254
    prism:volume = 24
    prism:issueIdentifier = 12
    prism:pageRange =
    prism:coverDate = 2022-12-01
    prism:coverDisplayDate = December 2022
    prism:doi = 10.1002/jgm.3458
    citedby-count = 7

    @_fa = true
    affilname = Université de Montréal, Faculté de Médecine
    affiliation-city = Montreal
    affiliation-country = Canada

    @_fa = true
    affilname = Centre Hospitalier de L'Université de Montréal
    affiliation-city = Montreal
    affiliation-country = Canada

    pubmed-id = 36279107
    prism:aggregationType = Journal
    subtype = re
    subtypeDescription = Review
    article-number = e3458
    source-id = 18922
    openaccess = 0
    openaccessFlag = false
    value:

    $ =

    value:

    $ =

    prism:isbn:

    @_fa =
    $ =

    pii =

    inizio

    @_fa = true

    @_fa = true
    @ref = self
    @href = https://api.elsevier.com/content/abstract/scopus_id/85112803548

    @_fa = true
    @ref = author-affiliation
    @href = https://api.elsevier.com/content/abstract/scopus_id/85112803548?field=author,affiliation

    @_fa = true
    @ref = scopus
    @href = https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85112803548&origin=inward

    @_fa = true
    @ref = scopus-citedby
    @href = https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85112803548&origin=inward

    Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering; Nano-Micro Letters; December 2021; DOI: 10.1007/s40820-021-00697-1
    prism:url = https://api.elsevier.com/content/abstract/scopus_id/85112803548
    dc:identifier = SCOPUS_ID:85112803548
    eid = 2-s2.0-85112803548
    dc:creator = Rahimnejad M.
    prism:publicationName = Nano-Micro Letters
    prism:issn = 23116706
    prism:eIssn = 21505551
    prism:volume = 13
    prism:issueIdentifier = 1
    prism:pageRange =
    prism:coverDate = 2021-12-01
    prism:coverDisplayDate = December 2021
    prism:doi = 10.1007/s40820-021-00697-1
    citedby-count = 40

    @_fa = true
    affilname = Centre Hospitalier de L'Université de Montréal
    affiliation-city = Montreal
    affiliation-country = Canada

    @_fa = true
    affilname = University of Montreal
    affiliation-city = Montreal
    affiliation-country = Canada

    pubmed-id =
    prism:aggregationType = Journal
    subtype = ar
    subtypeDescription = Article
    article-number = 182
    source-id = 21100203115
    openaccess = 1
    openaccessFlag = true
    value:

    $ = all

    $ = publisherfullgold

    $ = repository

    $ = repositoryvor

    value:

    $ = All Open Access

    $ = Gold

    $ = Green

    prism:isbn:

    @_fa =
    $ =

    pii =

    Last 5 articles (pubmed)

    • The impact of hUC MSC-derived exosome-nanoliposome hybrids on α-synuclein fibrillation and neurotoxicity

      Amyloid aggregation of α-synuclein (αSN) protein amplifies the pathogenesis of neurodegenerative diseases (NDs) such as Parkinson's disease (PD). Consequently, blocking aggregation or redirecting self-assembly to less toxic aggregates could be therapeutic. Here, we improve brain-specific nanocarriers using a hybrid of exosomes (Ex) from human umbilical cord mesenchymal stem cells (hUC MSCs) and nanoliposomes containing baicalein (Ex-NLP-Ba) and oleuropein (Ex-NLP-Ole). The hybrids contained both...

    • Viral and non-viral gene therapy using 3D (bio)printing

      The overall success in launching discovered drugs is tightly restricted to the high rate of late-stage failures, which ultimately inhibits the distribution of medicines in markets. As a result, it is imperative that methods reliably predict the effectiveness and, more critically, the toxicity of medicine early in the drug development process before clinical trials be continuously innovated. We must stay up to date with the fast appearance of new infections and diseases by rapidly developing the...

    • Prevascularized Micro-/Nano-Sized Spheroid/Bead Aggregates for Vascular Tissue Engineering

      Efficient strategies to promote microvascularization in vascular tissue engineering, a central priority in regenerative medicine, are still scarce; nano- and micro-sized aggregates and spheres or beads harboring primitive microvascular beds are promising methods in vascular tissue engineering. Capillaries are the smallest type and in numerous blood vessels, which are distributed densely in cardiovascular system. To mimic this microvascular network, specific cell components and proangiogenic...

    CONTACTS

    Working hours

    • Mon-Fri 09:00-15:00

    Links

    Facebook Twitter Instagram
    Created by An:Ca © 2023 Tor Vergata University P.I. 02133971008 – C.F. 80213750583